Similarly, RBP3 showed decreased expression in most tumor tissues, including BRCA, GBM, KICH, KIRC, KIRP, PRAD, THCA, and uterine corpus endometrial carcinoma (UCEC), while exhibiting increased expression in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), bladder urothelial carcinoma (BLCA), COAD, pheochromocytoma and paraganglioma (PCPG), and lung squamous cell carcinoma (LUSC) (Figure 1C). Here, RBP3 is linked to pheochromocytoma-paraganglioma.